Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 3-mer - A1B1C1 

Biological assembly 1 assigned by authors.

Macromolecule Content

• Total Structure Weight: 57.10 kDa 
• Atom Count: 4431 
• Modelled Residue Count: 500 
• Deposited Residue Count: 507 
• Unique protein chains: 3

4DTG

Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model

• DOI: 10.2210/pdb4DTG/pdb

• Classification: BLOOD CLOTTING INHIBITOR/IMMUNE SYSTEM
• Organism(s): Homo sapiens
• Expression System: Homo sapiens, Escherichia coli
• Mutation(s): No 


• Deposited: 2012-02-21 Released: 2012-06-13 
• Deposition Author(s): Svensson, L.A., Breinholt, J., Krogh, B.O., Hilden, I.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.80 Å
• R-Value Free: 0.236 
• R-Value Work: 0.196 
• R-Value Observed: 0.198 

Literature

Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.

Hilden, I., Lauritzen, B., Sorensen, B.B., Clausen, J.T., Jespersgaard, C., Krogh, B.O., Bowler, A.N., Breinholt, J., Gruhler, A., Svensson, L.A., Petersen, H.H., Petersen, L.C., Balling, K.W., Hansen, L., Hermit, M.B., Egebjerg, T., Friederichsen, B., Ezban, M., Bjorn, S.E.

(2012) Blood 119: 5871-5878

• PubMed: 22563084 
• DOI: 10.1182/blood-2012-01-401620
• Primary Citation of Related Structures:  
  4DTG


• PubMed Abstract: 
  

Hemophilia is treated by IV replacement therapy with Factor VIII (FVIII) or Factor IX (FIX), either on demand to resolve bleeding, or as prophylaxis. Improved treatment may be provided by drugs designed for subcutaneous and less frequent administration with a reduced risk of inhibitor formation. Tissue factor pathway inhibitor (TFPI) down-regulates the initiation of coagulation by inhibition of Factor VIIa (FVIIa)/tissue factor/Factor Xa (FVIIa/TF/FXa). Blockage of TFPI inhibition may facilitate thrombin generation in a hemophilic setting. A high-affinity (K(D) = 25pM) mAb, mAb 2021, against TFPI was investigated. Binding of mAb 2021 to TFPI effectively prevented inhibition of FVIIa/TF/FXa and improved clot formation in hemophilia blood and plasma. The binding epitope on the Kunitz-type protease inhibitor domain 2 of TFPI was mapped by crystallography, and showed an extensive overlap with the FXa contact region highlighting a structural basis for its mechanism of action. In a rabbit hemophilia model, an intravenous or subcutaneous dose significantly reduced cuticle bleeding. mAb 2021 showed an effect comparable with that of rFVIIa. Cuticle bleeding in the model was reduced for at least 7 days by a single intravenous dose of mAb 2021. This study suggests that neutralization of TFPI by mAb 2021 may constitute a novel treatment option in hemophilia.

---

Organizational Affiliation: 

Biopharmaceuticals Research Unit, Novo Nordisk, Maaloev, Denmark. [e-mail]

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Humanized recombinant FAB fragment, FAB 2021, of a murine antibody, light chain	L	219	Homo sapiens	Mutation(s): 0

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details	Image
Humanized recombinant FAB fragment, FAB 2021, of a murine antibody, heavy chain	H	222	Homo sapiens	Mutation(s): 0

Entity ID: 3
Molecule	Chains	Sequence Length	Organism	Details	Image
Tissue factor pathway inhibitor	K	66	Homo sapiens	Mutation(s): 0  Gene Names: LACI, TFPI, TFPI (AMINO ACIDS 119-178), TFPI1
Find proteins for P10646 (Homo sapiens) Explore P10646  Go to UniProtKB:  P10646
NIH Common Fund Data Resources
PHAROS:  P10646 GTEx:  ENSG00000003436

Small Molecules

Ligands 3 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
MES	H	2-(N-MORPHOLINO)-ETHANESULFONIC ACID C6 H13 N O4 S SXGZJKUKBWWHRA-UHFFFAOYSA-N
PGE	H	TRIETHYLENE GLYCOL C6 H14 O4 ZIBGPFATKBEMQZ-UHFFFAOYSA-N
GOL	H, L	GLYCEROL C3 H8 O3 PEDCQBHIVMGVHV-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.80 Å
• R-Value Free: 0.236 
• R-Value Work: 0.196 
• R-Value Observed: 0.198 
• Space Group: I 2 2 2

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 65.01	α = 90
b = 125.64	β = 90
c = 202.34	γ = 90

Software Package:

Software Name	Purpose
MxCuBE	data collection
PHASER	phasing
REFMAC	refinement
XDS	data reduction
XSCALE	data scaling

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2012-02-21 
• Released Date: 2012-06-13 
Deposition Author(s): Svensson, L.A., Breinholt, J., Krogh, B.O., Hilden, I.

Revision History  

• Version 1.0: 2012-06-13
  Type: Initial release
  
• Version 1.1: 2012-07-25
  Changes: Database references
• Version 1.2: 2018-03-07
  Changes: Data collection